The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cancer Research

• Publication date

  2006-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-05-2368PMID 16778220
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERBB4/HER4 Potentiates STAT5A Transcriptional Activity by Regulating Novel STAT5A Serine Phosphorylation Events*[boxs]

  2005cited by this paper
• Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In situ of the Breast

  2005cited by this paper
• Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

  2005cited by this paper
• Presenilin-dependent γ-Secretase Processing Regulates Multiple ERBB4/HER4 Activities*

  2005influential reference
• The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

  2004influential reference
• The structure of a Bcl-xL/Bim fragment complex: implications for Bim function.

  2003influential reference
• Neural and mammary gland defects in ErbB4 knockout mice genetically rescued from embryonic lethality

  2003cited by this paper
• Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis

  2003cited by this paper
• Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer

  2003cited by this paper
• Ways of dying: multiple pathways to apoptosis.

  2003influential reference
• Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5

  2003cited by this paper
• EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival

  2002cited by this paper
• BH3 - only proteins: evolutionarily conserved proapoptotic Bcl - 2 family members essential for init

  2002cited by this paper
• Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

  2002cited by this paper
• Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

  2002cited by this paper
• Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4.

  2002cited by this paper
• Presenilin-dependent γ-Secretase-like Intramembrane Cleavage of ErbB4*

  2002cited by this paper
• Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals

  2001cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens.

  2001cited by this paper
• BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

  2001cited by this paper
• γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase

  2001cited by this paper
• Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death

  2001cited by this paper
• HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells

  2001cited by this paper
• BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak.

  2001cited by this paper
• Different expression patterns of Bcl-2 family genes in breast cancer by estrogen receptor status with special reference to pro-apoptotic Bak gene

  2000cited by this paper
• c-erbB-4 protein expression in human breast cancer

  2000cited by this paper
• Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.

  2000cited by this paper
• Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4.

  2000cited by this paper
• Heregulin-dependent Trafficking and Cleavage of ErbB-4*

  2000cited by this paper
• Tumor Necrosis Factor-a-converting Enzyme Is Required for Cleavage of erbB4/HER4*

  2000cited by this paper
• Erbb4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation

  1999cited by this paper
• In vivo patterns of Bcl‐2 family protein expression in breast carcinomas in relation to apoptosis

  1999cited by this paper
• Cell Damage-induced Conformational Changes of the Pro-Apoptotic Protein Bak In Vivo Precede the Onset of Apoptosis

  1999cited by this paper
• c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer

  1998cited by this paper
• Expression of death‐related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas

  1998influential reference
• Two erbB-4 transcripts are expressed in normal breast and in most breast cancers

  1998cited by this paper
• Cells: a laboratory manual

  1997cited by this paper
• Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis

  1997cited by this paper
• Movement of Bax from the Cytosol to Mitochondria during Apoptosis

  1997cited by this paper

• Multiple Roles for Neuregulins and their ERBB Receptors in Neurodegenerative Disease Pathogenesis and Therapy.

  2025cites this paper
• Promising therapeutic targets for tumor treatment: Cleaved activation of receptors in the nucleus.

  2024cites this paper
• Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation

  2024cites this paper
• HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice

  2024cites this paper
• Structural dynamics of the active HER4 and HER2/HER4 complexes is finely tuned by different growth factors and glycosylation

  2024cites this paper
• A small-molecule pan-HER inhibitor alone or in combination with cisplatin exerts efficacy against nasopharyngeal carcinoma

  2023cites this paper
• Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy

  2023cites this paper
• The role of the NDRG1 in the pathogenesis and treatment of breast cancer.

  2023cites this paper
• Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy

  2023cites this paper
• An unbiased pathway analysis (UPA) designed for multi-omics inference of cell signaling pathways

  2022cites this paper
• ErbB4 in the brain: Focus on high grade glioma

  2022cites this paper
• ERBB and P‐glycoprotein inhibitors break resistance in relapsed neuroblastoma models through P‐glycoprotein

  2022cites this paper
• Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery

  2022cites this paper
• Molecular Recognition and Quantification of HER-3, HER-4 and HRG-α in Whole Blood and Tissue Samples Using Stochastic Sensors

  2022cites this paper
• "Shedding" light on HER4 signaling in normal and malignant breast tissues.

  2022cites this paper
• The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein

  2022influential citation
• Plasma Level’s of Neuregulin-1 in Healthy People

  2022cites this paper
• ErbB4‐mediated regulation of vasculogenic mimicry capability in breast cancer cells

  2021cites this paper
• Expression and Prognosis of HER Family in Breast Cancer

  2021cites this paper
• WW Domain-Containing E3 Ubiquitin Protein Ligase 1: A Self-Disciplined Oncoprotein

  2021cites this paper
• G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models

  2021cites this paper
• miR-93-5p knockdown repressed hepatocellular carcinoma progression via increasing ERBB4 and TETs-dependent DNA demethylation

  2021cites this paper
• The role of ERBB4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors

  2021cites this paper
• A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors

  2021cites this paper
• Control of cell death/survival balance by the MET dependence receptor

  2020cites this paper
• Therapeutic Role of Neuregulin 1 Type III in SOD1-Linked Amyotrophic Lateral Sclerosis

  2020cites this paper
• Functional role of WW domain‐containing proteins in tumor biology and diseases: Insight into the role in ubiquitin‐proteasome system

  2020cites this paper
• The role of ErbB4 in cancer

  2020cites this paper
• Her4 promotes cancer metabolic reprogramming via the c-Myc-dependent signaling axis.

  2020cites this paper
• Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking

  2020cites this paper
• Mechanisms of ERBB3 Action in Human Neoplasia.

  2019cites this paper
• RIP at the Synapse and the Role of Intracellular Domains in Neurons

  2019cites this paper
• A systems biology pipeline identifies regulatory networks for stem cell engineering

  2019cites this paper
• Biasing HER4 Tyrosine Kinase Signaling with Antibodies: Induction of Cell Death by Antibody-Dependent HER4 Intracellular Domain Trafficking

  2019influential citation
• Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer

  2019cites this paper
• Target HER four in breast cancer?

  2019cites this paper
• Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy

  2019cites this paper
• Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors*

  2019cites this paper
• Downregulation of miroRNA‐141 mediates acquired resistance to trastuzumab and is associated with poor outcome in breast cancer by upregulating the expression of ERBB4

  2019cites this paper
• ErbB4 3′-UTR Variant (c.*3622A>G) is Associated with ER/PR Negativity and Advanced Breast Cancer

  2018cites this paper
• Pan-HER-targeted approach for cancer therapy: Mechanisms, recent advances and clinical prospect.

  2018cites this paper
• HER4 gene expression in FFPE breast cancer patients

  2018cites this paper
• Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma

  2018cites this paper
• The intracellular domain of the leptin receptor prevents mitochondrial depolarization and mitophagy.

  2018cites this paper
• Sensitive molecular detection of small nodal metastasis in uterine cervical cancer using HPV16-E6/CK19/MUC1 cancer biomarkers

  2018cites this paper
• ErbB4 deletion accelerates renal fibrosis following renal injury.

  2018cites this paper
• Activation of ERBB4 in Glioblastoma Can Contribute to Increased Tumorigenicity and Influence Therapeutic Response

  2018cites this paper
• Implication du récepteur à activité tyrosine kinase (RTK) MET sur la balance survie/apoptose et identification de nouvelles mutations de RTKs dans les cancers colorectaux métastatiques

  2018cites this paper
• Gamma-secretase-dependent signaling of receptor tyrosine kinases

  2018cites this paper
• ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammation

  2017cites this paper
• Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer

  2017cites this paper
• Genome-wide screen of gamma-secretase–mediated intramembrane cleavage of receptor tyrosine kinases

  2017cites this paper
• HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

  2017cites this paper
• The association between rs1972820 and the risk of breast cancer in Isfahan population

  2017cites this paper
• SUMOylation regulates nuclear accumulation and signaling activity of the soluble intracellular domain of the ErbB4 receptor tyrosine kinase

  2017cites this paper
• Identification and characterization of ErbB4 kinase inhibitors for effective breast cancer therapy

  2017cites this paper
• KITENIN functions as a fine regulator of ErbB4 expression level in colorectal cancer via protection of ErbB4 from E3‐ligase Nrdp1‐mediated degradation

  2017cites this paper
• ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.

  2017cites this paper
• ERBB4 acts as a suppressor in the development of hepatocellular carcinoma

  2017cites this paper
• Her4 Promotes a Stem-like Phenotype in Osteosarcoma

  2016cites this paper
• A prostate-specific antigen-dependent fusion polypeptide inhibits growth of prostate cancer cells in vitro and in vivo.

  2016cites this paper
• Analysis of regulatory mechanism after ErbB4 gene mutation based on local modeling methodology.

  2016cites this paper
• Immunohistochemical expression of human epidermal growth factor receptor (HER)-4 and prognosis in patients with metastatic breast cancer.

  2016cites this paper
• The role of Her2 and other oncogenes of the PI3K/AKT pathway in mitochondria

  2016cites this paper
• The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

  2016cites this paper
• Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis

  2016cites this paper
• Receptor Tyrosine Kinases and Their Ligands

  2016cites this paper
• Tumor-promoting function of single nucleotide polymorphism rs1836724 (C3388T) alters multiple potential legitimate microRNA binding sites at the 3'-untranslated region of ErbB4 in breast cancer.

  2016cites this paper
• Prognostic value of ERBB4 expression in patients with triple negative breast cancer

  2016cites this paper
• Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling

  2016cites this paper
• The role of ADAM17 in tumorigenesis and progression of breast cancer

  2016cites this paper
• Analysis of regulatory mechanism after ErbB4 gene mutation based on local modeling methodology.

  2016cites this paper
• Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study

  2015cites this paper
• CHARACTERIZATION OF ERBB4 EXPRESSION IN OSTEOSARCOMA

  2015cites this paper
• The role of the EGFR and ERBB4 in acute pancreatitis

  2015cites this paper
• Détection moléculaire des métastases des ganglions lymphatique dans le cancer du col de l'utérus

  2015cites this paper
• BH3‐only proteins: a 20‐year stock‐take

  2015cites this paper
• A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.

  2015cites this paper
• Expresión diferencial de microRNAs en tumores de mujeres jóvenes con cáncer de mama: Cribado de dianas moleculares

  2015cites this paper
• Co-ordinated brain and craniofacial development depend upon Patched1/XIAP regulation of cell survival.

  2015cites this paper
• HER4 tumor expression in breast cancer patients randomized to treatment with or without tamoxifen.

  2015cites this paper
• Investigations into the role of the ErbB4 receptor in cardiomyocyte hypertrophy and adult cardiac function

  2015cites this paper
• Genetic variants in ERBB4 is associated with chronic hepatitis B virus infection

  2015cites this paper
• Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells

  2014cites this paper
• Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development

  2014cites this paper
• The localization of HER 4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER + HER 2-breast cancer

  2014cites this paper
• Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

  2014cites this paper
• Linear epitopes that generate anti-HER-2 antibody responses with trastuzuab- (herceptin) like biological activity

  2014cites this paper
• Marqueurs de réponse aux thérapies ciblées et personnalisation thérapeutique dans les cancers colorectaux métastatiques

  2014cites this paper
• Expression of the EGF Family in Gastric Cancer: Downregulation of HER4 and Its Activating Ligand NRG4

  2014cites this paper
• Genomics Convergent and Divergent Cellular Responses by ErbB 4 Isoforms in Mammary Epithelial Cells

  2014cites this paper
• Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer

  2014cites this paper
• New insights in the regulation of mitochondrial functions and metabolic reprogramming by ERBB receptors in cancer

  2014cites this paper
• Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer.

  2014cites this paper
• Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis

  2014cites this paper
• Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer

  2014cites this paper
• Effets des clivages du récepteur tyrosine kinase Met par les calpaïnes sur la motilité et la mort cellulaire

  2014cites this paper
• The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer

  2014cites this paper
• The dependence receptor TrkC triggers mitochondria-dependent apoptosis upon Cobra-1 recruitment.

  2013cites this paper
• Uncoupling Protein 2 Impacts Endothelial Phenotype via p53-Mediated Control of Mitochondrial Dynamics

  2013cites this paper